Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

First Edition

Research Article October 9 2025
Safety of Gemtuzumab Ozogamicin with Cytarabine, Daunorubicin, and Midostaurin Induction in FLT3-Mutated AML
Research Article October 9 2025
Targeting Dysregulated Epigenetic and Transcription Factor Networks in KMT2A-Rearranged AML Using iPSC Models
Brief Report October 9 2025
Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockade
Brief Report September 30 2025
Luspatercept treatment affects immune regulatory subsets in subjects with MDS with Ring Sideroblasts
Brief Report September 17 2025
Real-world Analysis of Polycythemia Vera Treatment Reveals Nonadherence to NCCN Guidelines in a Large Proportion of Patients
Brief Report September 17 2025
T cell immune profile changes predict durable response to nivolumab-rituximab in treatment naïve FL
Research Article September 1 2025
Inferior Survival in Double Refractory Large B-cell Lymphoma Eligible for third-line CD19 CAR T-cell Therapy
Research Article August 25 2025
Application of the International Working Group MDS Molecular Taxonomy Classes to a Single Institution Cohort
Research Article August 25 2025
Final Safety and Efficacy Results from a Phase 1/2 Study of Tagraxofusp, a CD123-Targeted Therapy, for Myelofibrosis
Research Article August 25 2025
Predicting Secondary Myeloid Neoplasms in Acquired Aplastic Anemia Using Machine Learning Models
Research Article August 19 2025
Second Malignancies among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib
Research Article August 19 2025
Azanucleoside treatment leads to B cell precursor acute lymphoblastic leukemia (BCP ALL)
Research Article August 5 2025
Disparities in Real-World Treatment Patterns of Hypomethylating Agents Among Patients with Myelodysplastic Syndromes in the US

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals